title: [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
abstract: OBJECTIVE
  To evaluate the toxicity and efficacy of capecitabine-based chemotherapy in the treatment of advanced gastric cancer.
  
  
  METHODS
  104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept. 2001 to May 2007. Group 1 was treated by capecitabine 1000 mg/m(2) orally twice daily on D1-14, repeated every 3 weeks;group 2 by capecitabine as that of group 1, and combined with paclitaxel 175 mg/m(2) intravenous infusion on D1 (or 80 - 90 mg/m(2) on D1, D8), or docetaxel 65 - 75 mg/m(2) on D1, repeated every 3 weeks; group 3 by capecitabine as that of group 1, combined with cisplatin 15 - 20 mg/m(2) intravenous infusion for 2 h on D1-5, or oxaliplatin 130 mg/m(2) for 2 h on D1, repeated every 3 weeks. The median cycles of treatment were 3 cycles.
  
  
  RESULTS
  The overall response rate was 20.6%. The median overall survival and the median time to progression were 8.5 months and 5.2 months, respectively. For the first-line chemotherapy, ORR was 40.0%, disease control rate was 76.7%; the median overall survival in all patients and in the patients with first-line chemotherapy of capecitabine plus paclitaxel were 10.9 months and 12.8 months, respectively. The adverse events in capecitabine alone group were the least among all the groups.
  
  
  CONCLUSIONS
  The capecitabine-based chemotherapy was effective and tolerable. The patients with KPS < 80 may choose capecitabine alone for the chemotherapy. The regimen of capecitabine combined with paclitaxel was more effective than other regimens. However, further investigation to improve it is still required.
authors.affiliation: Department of Gastrointestinal Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Ya
authors.initials: Y
authors.lastname: Xiao
authors.forename: Ming
authors.initials: M
authors.lastname: Lu
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: Shen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced; D055815:Young Adult
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil